Multicenter, Open-Label, Uncontrolled Study to Investigate the Impact of Weight and BMI on Inhibition of Ovulation of a Transdermal Patch Formulation Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene in Young Female Volunteers Stratified by BMI Over a Period of 3 Treatment Cycles.
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 18 Feb 2010 Actual patient number (168) added as reported by ClinicalTrials.gov.